D. Mendeleev University of Chemical Technology of Russia
Brief summary
The antithrombotic activity of five synthesized PPAR delta / beta agonists (2-methyl-4-[4-methyl-2-(4-trifluoromethylphenyl)-1,3-thiazole-5-ilmethylthio]-phenoxy)acetic acid was investigated as well as its two metabolites and two triazole analogues by measuring platelet aggregation in platelet-rich plasma. It was established that the sulfonic derivative of methylthiazole-containing acid has the highest antithrombotic activity.
2. Ivashkin V.T. i Maevskaya M.V. Lipotoksichnost i metabolicheskie narysheniya pri ojirenii // RJGGK. 2010, 1(1), 4-13.
3. Bazi dannih farmakologicheskih receptorov i deistvyushie na nih soedineniya ?The IUPHAR / BPS GuidetoPharmacology? [sait]. URL: http://www.guidetopharmacology.org
4. Karthick T., Tandon P. and Singh S. Evaluation of structural isomers, molecular interactions, reactivity descriptors and vibrational analysis of tretinoin // Anal. Sci. 2017, 33, 83-87.
5. Thacher S. M., Vasudevan J. and Chandraratna R. A. Therapeutic applications for ligands of retinoid receptors // Curr. Pharm. 2000, Des., 6, 25-58.
6. Shen L., Zhang Y., Wang A., Sieber-McMaster E., Chen X., Pelton P., Xu J.Z., Yang M., Zhu P., Zhou L., Reuman M., Hu Z., Russell R., Gibbs A.C., Ross H., Demarest K., Murray W.V. and Kuo G.H. Synthesis and identification of [1,2,4]thiadiazole derivatives as a new series of potent and orally active dual agonists of peroxisome proliferator-activated receptors α and δ // J. Med. Chem. 2007, 50, 3954-3963.
7. Shen L.,?Zhang Y.,?Wang A.,?Sieber-McMaster E.,?Chen X.,?Pelton P.,?Xu J.Z.,?Yang M.,?Zhu P.,?Zhou L.,?Reuman M.,?Hu Z.,?Russell R.,?Gibbs A.C.,?Ross H.,?Demarest K.,?Murray W.V. and?Kuo G.H. Synthesis and structure?activity relationships of thiadiazole-derivatives as potent and orally active peroxisome proliferator-activated receptors α/δ dual agonists // Bioorg. Med. Chem. 2008, 16, 3321-3341.
8. Yin Y., Russell R.G., Dettin L.E., Bai R., Wei Z.L., Kozikowski A.P., Kopleovich L. and Glazer R.I. Peroxisome proliferator-activated receptor δ and γ agonists differentially alter tumor differentiation and progression during mammary carcinogenesis // J. Cancer Res. 2005, 65 (9), 3950-3957.
9. Inoue H., Tanabe T. and Umesono K. Feedback Control of Cyclooxygenase-2 Expression through PPARγ // Biol. Chem. 2000, 275(36), 28028-32.
10. Huang J.T., Welch J.S., Ricote M., Binder C.J., Willson T.M., Kelly C., Witztum J.L., Funkk C.D., Conrad D. and Glass C.K. Interleukin-4-dependent production of PPAR-δ ligands in macrophages by 12/15-lipoxygenase // Nature. 1999, 400(6742), 378-82.
11. Becker J., Delayre-Orthez C., Frossard N. and Pons F. Regulation of peroxisome proliferator-activated receptor-α expression during lung inflammation // Pulm. Pharmacol. 2008, Ther., 21(2), 324-30.
12. Necela B.M., Su W. and Thompson E.A. Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor c and nuclear factor-kB in macrophages // Immunol. 2008, 125(3), 344-358.
13. Barish G.D., Downes M., Alaynick W.A., Yu R.T., Ocampo C.B., Bookout A.L., Mangelsdorf D.J. and Evans R.M. A Nuclear Receptor Atlas: Macrophage Activation // J. Mol. Endocrinol. 2005 19(10), 2466-77.
14. Leininger M.T., Portocarrero C.P. and Houseknecht K.L. Peroxisome proliferator-activated receptor γ1 expression in porcine white blood cells: dynamic regulation with acute endotoxemia Biochem. Biophys. Res. Commun. 1999, 263(3), 749-53.
16. Pivovarova?E.N., Dyshkin?M.I., Perepechaeva?M.L., Kobzev?V.F., Tryfakin?V.A. i Markel?A.L. Vse priznaki metabolicheskogo sindroma y gipertenzivnoi linii kris NISAG associiryutsya s povishennoi aktivnostu faktorov transkripcii PPAR, LXR, PXR i CARr v pecheni // Biomedicinskaya himiya. 2011, 57 (4), 435-445.
17. Wensaas A.J., Rustan A., Lovstedt K., Kull B., Wikstrom S., Drevon C. and Hallen S. Cell-based multiwell assays for the detection of substrate accumulation and oxidation // J. Lipid Res. 2007, 48, 961-967.
18. Ferhana Y.A., Matthew G.H., Desvergne B., Warner T.D. and Mitchell J.A. PPAR β/δ Agonists Modulate Platelet Function via a Mechanism Involving PPAR Receptors and Specific Association/Repression of PKCα?Brief Report // ArteriosclerThrombVasc Biol. 2009, 29, 1871-1873.
19. Vasina L.V., Veselkina O.S. i Petrishev N.N. Mehanizmi vliyaniya preparata ?Ozagrel? na agregacionnyu aktivnost trombocitov // Regionalnoe krovoobrashenie i mikrocirkylyaciya. 2012, 11, 3 (43),76-80.
20. Thevis M., Moller I., Thomas A., Beuck S., Rodchenkov G., Bornatsch W., Geyer H. and Schanzer W. Characterization of two major urinary metabolites of the PPARδ-agonist GW1516 and implementation of the drug in routine doping controls // Anal BioanalChem. 2010, 396, 2479?2491.
21. Virus E. and Rodchenkov G. Detection of PPARδ agonists GW1516 and GW0742 and their metabolites in human urine // Drug Test. Analysis. 2012, 4, 754?760.
22. Ciocoiu C.C., Nikolis N., Nguyen H.H., G. Thoresen H., Aasen A.J. and Hansen T.V. Synthesis and dual PPARα/δ agonist effects of 1,4-disubstituted 1,2,3-triazole analogues of GW 501516 J. Med. Chim. 2010, 45, 7, 3047-3055.
23. Born G.V. Aggregation of blood platelets by adenosine diphosphate and its reversal // Nature. 1962, 194, 927-929.